| Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2–positive breast cancer J Shou, S Massarweh, CK Osborne, AE Wakeling, S Ali, H Weiss, R Schiff Journal of the National Cancer Institute 96 (12), 926-935, 2004 | 1358 | 2004 |
| Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer CK Osborne, J Shou, S Massarweh, R Schiff Clinical cancer research 11 (2), 865s-870s, 2005 | 509 | 2005 |
| Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function S Massarweh, CK Osborne, CJ Creighton, L Qin, A Tsimelzon, S Huang, ... Cancer research 68 (3), 826-833, 2008 | 503 | 2008 |
| Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance R Schiff, SA Massarweh, J Shou, L Bharwani, SK Mohsin, CK Osborne Clinical Cancer Research 10 (1), 331s-336s, 2004 | 484 | 2004 |
| Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response R Schiff, S Massarweh, J Shou, CK Osborne Clinical Cancer Research 9 (1), 447s-454s, 2003 | 429 | 2003 |
| Treatment of human epidermal growth factor receptor 2–overexpressing breast cancer xenografts with multiagent HER-targeted therapy G Arpino, C Gutierrez, H Weiss, M Rimawi, S Massarweh, L Bharwani, ... Journal of the National Cancer Institute 99 (9), 694-705, 2007 | 208 | 2007 |
| Resistance to endocrine therapy in breast cancer: exploiting estrogen receptor/growth factor signaling crosstalk S Massarweh, R Schiff Endocrine-related cancer 13 (Supplement_1), S15-S24, 2006 | 194 | 2006 |
| Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor–positive, HER-2/neu-positive breast cancer S Massarweh, CK Osborne, S Jiang, AE Wakeling, M Rimawi, SK Mohsin, ... Cancer research 66 (16), 8266-8273, 2006 | 179 | 2006 |
| Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators R Schiff, SA Massarweh, J Shou, L Bharwani, G Arpino, M Rimawi, ... Cancer chemotherapy and pharmacology 56 (1), 10-20, 2005 | 178 | 2005 |
| Unraveling the mechanisms of endocrine resistance in breast cancer: new therapeutic opportunities S Massarweh, R Schiff Clinical Cancer Research 13 (7), 1950-1954, 2007 | 155 | 2007 |
| Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts CJ Creighton, S Massarweh, S Huang, A Tsimelzon, SG Hilsenbeck, ... Cancer research 68 (18), 7493-7501, 2008 | 144 | 2008 |
| Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts MF Rimawi, LS Wiechmann, YC Wang, C Huang, I Migliaccio, MF Wu, ... Clinical Cancer Research 17 (6), 1351-1361, 2011 | 85 | 2011 |
| Erratum to: A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure S Massarweh, E Romond, EP Black, E Van Meter, B Shelton, ... Breast cancer research and treatment 149 (2), 565-565, 2015 | 67* | 2015 |
| A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure S Massarweh, E Romond, EP Black, E Van Meter, B Shelton, ... Breast cancer research and treatment 143 (2), 325-332, 2014 | 66 | 2014 |
| Textbook of uncommon cancer D Raghavan, MS Ahluwalia, CD Blanke, J Brown, ES Kim, GH Reaman, ... John Wiley & Sons, 2017 | 64 | 2017 |
| Prevalence of hormone receptors and HER2/neu in breast cancer cases in Jordan MA Sughayer, MM Al-Khawaja, S Massarweh, M Al-Masri Pathology & Oncology Research 12 (2), 83-86, 2006 | 55 | 2006 |
| ErbB3 downregulation enhances luminal breast tumor response to antiestrogens MM Morrison, K Hutchinson, MM Williams, JC Stanford, JM Balko, ... The Journal of clinical investigation 123 (10), 4329-4343, 2013 | 53 | 2013 |
| Inhibition of epidermal growth factor/HER2 receptor signaling using ZD1839 (Iressa) restores tamoxifen sensitivity and delays resistance to estrogen deprivation in HER2 … S Massarweh, J Shou, SK Mohsin, M Ge, AE Wakeling, CK Osborne, ... Proc Am Soc Clin Oncol 21, 33a, 2002 | 45 | 2002 |
| Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and … A Alqaisi, L Chen, E Romond, M Chambers, M Stevens, G Pasley, ... Breast cancer research and treatment 148 (2), 437-444, 2014 | 39 | 2014 |
| Molecular Characterization and Mortality From Breast Cancer in Men SA Massarweh, GW Sledge, DP Miller, D McCullough, VI Petkov, S Shak Journal of Clinical Oncology 36 (14), 1396-1404, 2018 | 38 | 2018 |
Rachel SchiffBaylor College of MedicineVerified email at bcm.edu
